文献速递妇科

二次肿瘤细胞减灭术对接受初始新辅助化疗及间歇性肿瘤细胞减灭术的铂敏感复发性卵巢癌的影响

The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery.
PubMed 文献 · Gynecol Oncol · 2022-04-06

回顾性单中心队列纳入272例铂敏感复发性上皮性卵巢癌患者,其中初治接受间歇性肿瘤细胞减灭术者107例(39.3%)。二次肿瘤细胞减灭术在中位无进展生存期(21个月 vs 21个月,p=0.684)和复发后生存期(81个月 vs 77个月,p=0.574)上与初治直接手术者无显著差异,现有筛选模型在间歇性肿瘤细胞减灭术组同样适用。

要点

  • 初治直接手术与间歇性肿瘤细胞减灭术组中位无进展生存期均为21个月(p=0.684)。
  • 两组中位复发后生存期分别为81个月与77个月(p=0.574),无显著差异。
  • PET/CT联合腹腔镜可准确预测二次肿瘤细胞减灭术无肉眼残留。

核心结论

  • 接受新辅助化疗及间歇性肿瘤细胞减灭术作为初始治疗的铂敏感复发性上皮性卵巢癌患者,其复发后生存结局与初治直接手术者相似。
  • 现有用于筛选二次肿瘤细胞减灭术患者的模型可安全应用于间歇性肿瘤细胞减灭术患者。

研究设计与样本

  • 回顾性、观察性、单中心队列研究,纳入2012年11月至2020年11月期间伴有腹部/腹股沟/心膈区疾病的铂敏感复发性上皮性卵巢癌患者。
  • 共纳入272例患者,其中165例(60.7%)初治接受直接肿瘤细胞减灭术,107例(39.3%)接受间歇性肿瘤细胞减灭术。
  • 通过PET/CT扫描和诊断性腹腔镜筛选手术候选者,178例(65.4%)接受了二次肿瘤细胞减灭术,其中155/178例(87.1%)达到完全肉眼切除。

主要发现

  • 初治直接手术组与间歇性肿瘤细胞减灭术组的中位无进展生存期分别为21个月与21个月(p=0.684),无显著差异。
  • 初治直接手术组与间歇性肿瘤细胞减灭术组的中位复发后生存期分别为81个月与77个月(p=0.574),无显著差异。
  • 在间歇性肿瘤细胞减灭术组和直接手术组中,现有筛选模型均表现良好,PET/CT联合腹腔镜能准确预测二次肿瘤细胞减灭术时无肉眼残留病变。

临床怎么用

  • 作者认为,现有筛选二次肿瘤细胞减灭术患者的模型可安全应用于初治接受间歇性肿瘤细胞减灭术的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aims of the present study were to assess the oncological outcomes of platinum-sensitive recurrent ovarian cancer patients undergoing secondary cytoreduction (SCS) after treatment with neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) at diagnosis and to compare the performance of different selection models in these patients. METHODS: Retrospective, observational, single-center cohort study including patients with platinum-sensitive recurrent epithelial ovarian cancer with abdominal/inguinal/cardiophrenic disease between November 2012 and November 2020. Patients were selected as surgical candidates with PET/CT-scan and with diagnostic laparoscopy. RESULTS: 272 patients were included in the study. Of these, 165 (60.7%) patients were treated with PDS at diagnosis and 107 (39.3%) with IDS. SCS was performed in 178 (65.4%) cases, with complete gross resection achieved in 155/178 (87.1%). No progression-free survival (PFS) difference was demonstrated when patients treated with PDS were compared with those treated with NACT+IDS at first diagnosis (median 21 versus 21 months; p = 0.684); no post-recurrence survival (PRS) difference was evident between the two groups (median 81 versus 77 months, respectively; p = 0.574). Current selection models to candidate patients to SCS adequately performed in patients treated with IDS at diagnosis, as well as in the PDS group, with combination of PET/CT-scan and laparoscopy being an accurate tool in prediction of no gross residual disease at SCS in this pre-selected population. CONCLUSIONS: Patients with platinum-sensitive recurrent epithelial ovarian cancer treated with NACT/IDS as primary treatment have similar post-recurrence survival outcomes of those treated with PDS. Current models to select patients for SCS can be safely applied to IDS patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Bizzarri N, Marchetti C, Conte C, et al. The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery. Gynecol Oncol. 2022. PMID: 35397918. doi:10.1016/j.ygyno.2022.03.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。